Nymox Pharmaceutical Corp (NYMX)

3.69
NASDAQ : Health Care
Prev Close 3.69
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.79 / 4.37
Avg Volume 257.30K
Exchange NASDAQ
Shares Outstanding 44.79M
Market Cap 177.36M
EPS -0.50
P/E Ratio 10.70
Div & Yield N.A. (N.A)

Latest News

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own companies lately.

4 Biotech Stocks Under $10 to Trade for Breakouts

4 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

Nymox Pharmaceutical (NYMX) Stock Higher on Positive Test Results

Nymox Pharmaceutical (NYMX) Stock Higher on Positive Test Results

Nymox Pharmaceutical (NYMX) shares continue to climb on promising BPH treatment candidate results.

Nymox Announces $850,000 Financing

Nymox Announces $850,000 Financing

Nymox Pharmaceuticals (NYMX) Stock Drops Today Following Monday's Climb

Nymox Pharmaceuticals (NYMX) Stock Drops Today Following Monday's Climb

Shares of Nymox Pharmaceuticals (NYMX) were down in late morning trading Tuesday as investors took some profits following the stock's surge on Monday.

Nymox Pharmaceuticals (NYMX) Stock Spikes Today on Prostate Cancer Trial Data

Nymox Pharmaceuticals (NYMX) Stock Spikes Today on Prostate Cancer Trial Data

Shares of Nymox Pharmaceuticals (NYMX) surged Monday after the company announced long-term clinical trial results from its NX-1207 Phase 2 prostate cancer study NX03-0040.

Nymox Announces New Prostate Cancer Clinical Trial Results

Nymox Announces New Prostate Cancer Clinical Trial Results

Significantly Better Clinical Outcomes After Up to 2.8 Years for NX-1207 Prostate Cancer Treated Patients Compared to Control Group

Nymox Pharmaceuticals (NYMX) Stock Declines Today After Week of Significant Gains

Nymox Pharmaceuticals (NYMX) Stock Declines Today After Week of Significant Gains

Shares of Nymox Pharmaceuticals (NYMX) were down Monday as investors took profits following four straight days of gains last week in which the stock rose more than 175%.

Nymox Pharmaceutical (NYMX) Surges After Late-Stage Trial Analysis Announcement

Nymox Pharmaceutical (NYMX) Surges After Late-Stage Trial Analysis Announcement

Shares of Nymox Pharmaceutical (NYMX) soared in afternoon trading Thursday after the company announced Wednesday that it would begin further analyses of its Phase 3 studies of NX-1207.

Nymox Announces Phase 3 BPH Studies

Nymox Announces Phase 3 BPH Studies

Nymox Reports 2014 Financial Results

Nymox Reports 2014 Financial Results

4 Stocks Under $10 Making Big Moves Higher

4 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

UPDATE - UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Nymox Pharmaceutical Corporation And Its Board Of Directors And A Lead Plaintiff Deadline Of January 26, 2015

UPDATE - UPCOMING DEADLINE: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Nymox Pharmaceutical Corporation And Its Board Of Directors And A Lead Plaintiff Deadline Of January 26, 2015

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox"...

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceutical Corporation To Contact Brower Piven Before The January 26, 2015 Lead Plaintiff Deadline In Class Action Lawsuit

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Nymox Pharmaceutical Corporation To Contact Brower Piven Before The January 26, 2015 Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of...

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Nymox Pharmaceutical Corporation And Its Board Of Directors And A Lead Plaintiff Deadline Of January 26, 2015

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors Of Class Action Against Nymox Pharmaceutical Corporation And Its Board Of Directors And A Lead Plaintiff Deadline Of January 26, 2015

Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation ("Nymox"...